Advanced in Myeloproliferative Neoplasms (MPN)

Edgar F. Jost

Aachen, NW, DE 
Advanced in Myeloproliferative Neoplasms (MPN)
Aachen, NW, DE 
OverviewLocationsClinical Research

Overview

Edgar Jost practices in Aachen, Germany. Mr. Jost is rated as an Advanced expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant.

His clinical research consists of co-authoring 98 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Myeloproliferative Neoplasms (MPN).

Gender
Male

Locations

Aachen, NW, Germany
Other Locations
Bonn, NW, Germany
Duesseldorf, NW, Germany
Max Von Laue Str. 9, Frankfurt Am Main, HE 60438, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)
Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug, Procedure
Study Drug: Ruxolitinib continuous therapy
Study Phase: Phase 2
IDH2-Post-Allo-Trial: Enasidenib As Consolidation or Salvage Therapy for Patients with IDH2 Mutated AML or MDS Following Allogeneic Blood Stem Cell Transplantation
IDH2-Post-Allo-Trial: Enasidenib As Consolidation or Salvage Therapy for Patients with IDH2 Mutated AML or MDS Following Allogeneic Blood Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Enasidenib
Study Phase: Phase 2
Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML
Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

98 Total Publications

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.
Journal: Leukemia
Published: April 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jost's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile